{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:54:57Z","timestamp":1788256497733,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40256-020-00416-y","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T01:02:32Z","timestamp":1590627752000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"21","author":[{"given":"Diyu","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6378-5402","authenticated-orcid":false,"given":"Yunqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"416_CR1","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/echo.14419","volume":"36","author":"M Cameli","year":"2019","unstructured":"Cameli M, Incampo E, Navarri R, et al. Effects of levosimendan in heart failure: the role of echocardiography. Echocardiography (Mount Kisco, NY). 2019;36:1566\u201372.","journal-title":"Echocardiography (Mount Kisco, NY)"},{"key":"416_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810\u201352.","journal-title":"Circulation"},{"key":"416_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jchf.2016.05.001","volume":"4","author":"V Xanthakis","year":"2016","unstructured":"Xanthakis V, Enserro DM, Larson MG, et al. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail. 2016;4:808\u201315.","journal-title":"JACC Heart Fail"},{"key":"416_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mhj.2003.50","volume":"145","author":"JM Aranda Jr","year":"2003","unstructured":"Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003;145:324\u20139.","journal-title":"Am Heart J"},{"key":"416_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.healun.2003.08.017","volume":"23","author":"SC Brozena","year":"2004","unstructured":"Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. 2004;23:1082\u20136.","journal-title":"J Heart Lung Transplant"},{"key":"416_CR6","doi-asserted-by":"publisher","first-page":"H131","DOI":"10.1152\/ajpheart.2002.282.1.H131","volume":"282","author":"K Brixius","year":"2002","unstructured":"Brixius K, Reicke S, Schwinger RHG. Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol. 2002;282:H131\u2013H137137.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"416_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, \u00c9des I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82\u20137.","journal-title":"Int J Cardiol"},{"key":"416_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/sj.bjp.0707157","volume":"150","author":"M Louhelainen","year":"2007","unstructured":"Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl\/Rapp rats. Br J Pharmacol. 2007;150:851\u201361.","journal-title":"Br J Pharmacol"},{"key":"416_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16:898\u2013906.","journal-title":"Eur J Heart Fail"},{"key":"416_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Comin-Colet","year":"2018","unstructured":"Comin-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128\u201336.","journal-title":"Eur J Heart Fail"},{"key":"416_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.08.188","volume":"202","author":"S Silvetti","year":"2016","unstructured":"Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol. 2016;202:138\u201343.","journal-title":"Int J Cardiol"},{"key":"416_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijcard.2014.04.111","volume":"174","author":"MS Nieminen","year":"2014","unstructured":"Nieminen MS, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol. 2014;174:360\u20137.","journal-title":"Int J Cardiol"},{"key":"416_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00392-013-0649-z","volume":"103","author":"S Silvetti","year":"2014","unstructured":"Silvetti S, Greco T, Di Prima AL, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials. Clin Res Cardiol. 2014;103:505\u201313.","journal-title":"Clin Res Cardiol"},{"key":"416_CR14","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:CD000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"416_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1\u2013e34.","journal-title":"PLoS Med"},{"key":"416_CR16","first-page":"2439","volume":"21","author":"D Zhang","year":"2015","unstructured":"Zhang D, Yao Y, Qian J, Huang J. Levosimendan improves clinical outcomes of refractory heart failure in elderly Chinese patients. Med Sci Mon Int Med J Exp Clin Res. 2015;21:2439\u201345.","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"key":"416_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5603\/CJ.a2014.0044","volume":"22","author":"E Oner","year":"2015","unstructured":"Oner E, Erturk M, Birant A, et al. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure. Cardiol J. 2015;22:87\u201393.","journal-title":"Cardiol J"},{"key":"416_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ehf2.12047","volume":"2","author":"S Mushtaq","year":"2015","unstructured":"Mushtaq S, Andreini D, Farina S, et al. Levosimendan improves exercise performance in patients with advanced chronic heart failure. ESC Heart Fail. 2015;2:133\u201341.","journal-title":"ESC Heart Fail"},{"key":"416_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","volume":"60","author":"G Malfatto","year":"2012","unstructured":"Malfatto G, Della Rosa F, Villani A, et al. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol. 2012;60:450\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"416_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijcard.2011.03.013","volume":"159","author":"MJ Bonios","year":"2012","unstructured":"Bonios MJ, Terrovitis JV, Drakos SG, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol. 2012;159:225\u20139.","journal-title":"Int J Cardiol"},{"key":"416_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10557-007-6034-2","volume":"21","author":"JT Parissis","year":"2007","unstructured":"Parissis JT, Papadopoulos C, Nikolaou M, et al. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther. 2007;21:263\u20138.","journal-title":"Cardiovasc Drugs Ther"},{"key":"416_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ejheart.2007.10.002","volume":"9","author":"I Ikonomidis","year":"2007","unstructured":"Ikonomidis I, Parissis JT, Paraskevaidis I, et al. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail. 2007;9:1172\u20137.","journal-title":"Eur J Heart Fail"},{"key":"416_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejheart.2006.06.001","volume":"9","author":"R Berger","year":"2007","unstructured":"Berger R, Moertl D, Huelsmann M, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail. 2007;9:202\u20138.","journal-title":"Eur J Heart Fail"},{"key":"416_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.ejheart.2005.02.002","volume":"7","author":"C Avgeropoulou","year":"2005","unstructured":"Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005;7:882\u20137.","journal-title":"Eur J Heart Fail"},{"key":"416_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776\u2013803.","journal-title":"J Am Coll Cardiol"},{"key":"416_CR26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1586\/14779072.2015.1071664","volume":"13","author":"N Ibrahim","year":"2015","unstructured":"Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015;13:1017\u201330.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"416_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303\u201312.","journal-title":"Int J Cardiol"},{"key":"416_CR28","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.jacc.2009.01.075","volume":"53","author":"M Gheorghiade","year":"2009","unstructured":"Gheorghiade M, Pang PS. Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? J Am Coll Cardiol. 2009;53:2349\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"416_CR29","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2018.03.454","volume":"71","author":"N Vodovar","year":"2018","unstructured":"Vodovar N, Logeart D. Similar BNP and mortality association in patients with and without heart failure: any increase matters. J Am Coll Cardiol. 2018;71:2089\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"416_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/ejhf.19","volume":"16","author":"M Toma","year":"2014","unstructured":"Toma M, Ezekowitz JA, Bakal JA, et al. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. Eur J Heart Fail. 2014;16:334\u201341.","journal-title":"Eur J Heart Fail"},{"key":"416_CR31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.amjcard.2011.06.045","volume":"108","author":"AO Badheka","year":"2011","unstructured":"Badheka AO, Rathod A, Kizilbash MA, et al. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol. 2011;108:1283\u20138.","journal-title":"Am J Cardiol"},{"key":"416_CR32","doi-asserted-by":"crossref","first-page":"e001626","DOI":"10.1161\/JAHA.114.001626","volume":"4","author":"WK Laskey","year":"2015","unstructured":"Laskey WK, Alomari I, Cox M, et al. Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2015;4:e001626.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"416_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ijcard.2018.02.067","volume":"259","author":"P Dilaveris","year":"2018","unstructured":"Dilaveris P, Tousoulis D. Big data analysis from Sweden confirms that resting heart rate in late adolescence is significantly associated with incident heart failure and all-cause mortality. Int J Cardiol. 2018;259:220\u20131.","journal-title":"Int J Cardiol"},{"key":"416_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","volume":"38","author":"CL Tacon","year":"2012","unstructured":"Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med. 2012;38:359\u201367.","journal-title":"Intensive Care Med"},{"key":"416_CR35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1517\/13543780902922660","volume":"18","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, Parissis JT, Starling RC, et al. Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs. 2009;18:695\u2013707.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00416-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T06:33:32Z","timestamp":1666679612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00416-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00416-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Diyu Cui, Yimeng Liao, Gege Li, and Yunqing Chen declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}